KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 108 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q3 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $224,785 | +23.2% | 12,941 | -0.1% | 0.00% | – |
Q2 2023 | $182,392 | +36.6% | 12,954 | +4.4% | 0.00% | – |
Q1 2023 | $133,553 | -28.2% | 12,412 | 0.0% | 0.00% | – |
Q4 2022 | $185,932 | +6.8% | 12,412 | -8.5% | 0.00% | – |
Q3 2022 | $174,162 | +29.2% | 13,564 | -2.5% | 0.00% | – |
Q2 2022 | $134,788 | -3.1% | 13,910 | -0.6% | 0.00% | – |
Q1 2022 | $139,140 | -30.1% | 13,998 | -17.3% | 0.00% | – |
Q4 2021 | $199,000 | -1.5% | 16,931 | -4.5% | 0.00% | – |
Q3 2021 | $202,000 | -22.0% | 17,725 | -4.8% | 0.00% | – |
Q2 2021 | $259,000 | -17.8% | 18,623 | +9.4% | 0.00% | – |
Q1 2021 | $315,000 | +5.0% | 17,016 | +0.4% | 0.00% | – |
Q4 2020 | $300,000 | +25.5% | 16,950 | +8.5% | 0.00% | – |
Q3 2020 | $239,000 | -24.6% | 15,621 | +27.9% | 0.00% | – |
Q2 2020 | $317,000 | +103.2% | 12,209 | +21.0% | 0.00% | – |
Q1 2020 | $156,000 | +69.6% | 10,088 | -4.1% | 0.00% | – |
Q3 2019 | $92,000 | -34.8% | 10,514 | +1.3% | 0.00% | – |
Q2 2019 | $141,000 | – | 10,381 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 2,474,561 | $42,983,125 | 5.17% |
Rubric Capital Management LP | 3,077,449 | $53,455,289 | 2.00% |
Parkman Healthcare Partners LLC | 509,810 | $8,855,400 | 1.62% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $10,422,000 | 1.47% |
AlphaCentric Advisors LLC | 110,000 | $1,910,700 | 1.08% |
Lion Point Capital, LP | 130,691 | $2,270,103 | 1.01% |
RICE HALL JAMES & ASSOCIATES, LLC | 650,366 | $11,296,857 | 0.72% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 185,853 | $3,228,267 | 0.53% |
ADVISORY RESEARCH INC | 204,098 | $3,545,182 | 0.49% |
Jackson Creek Investment Advisors LLC | 65,607 | $1,140 | 0.48% |